A microchip engineer might seem like an odd fit for a keynote speaker at an event focused on cell therapy, but at Science for health Peter Peumans will be presenting one of the day’s visionary talks. Peumans will draw on his experience with the tech powerhouse imec to give us an insider’s perspective on the role new chip technologies may soon take on in the cell therapy field.
In this article, V-Bio Ventures introduces one of their portfolio companies, OCTIMET. This Belgian oncology startup just added a new member to its executive team, with the appointment of Shelley Margetson as CEO. It’s exciting times for OCTIMET, who are gearing up for a series B with their sights set on potential partners in China.
Science for health is Belgium’s new research event, set to promote more collaborations in our stellar life sciences ecosystem. The September event will bring together experts from across the board; academics, industry leaders, clinicians and service providers; facilitating the formation of new research connections. The ultimate aim is not only to showcase Belgian research, but to create value for patients by encouraging new and innovative partnerships. For the inaugural 2019 edition, the focus is on the exciting field of cell therapy.
This month marked the crystal anniversary of the life sciences networking event Knowledge for Growth. The event was a huge success, with 1300+ attendees representing 600+ companies from 20+ countries around the world. The theme for this year was “Precision in Life Sciences”, with the fascinating plenary talks discussing the effect of digitalization on healthcare.
Just days before KBC Securities’ "State of the Union" announcement on how well Belgian biotech has been faring in 2019, Confo Therapeutics closed a terrific series A financing round. The company raised 30 million euros, which will be used to accelerate their drug discovery activities using their camelid-based ConfoBody™ technology.
Bioscience engineers at KU Leuven have created a record-breaking hydrogen gas panel. The panel is capable of producing 250 liters of hydrogen gas per day; enough that just 20 panels could provide a family’s electricity and heating needs for a whole European winter. The Belgian device is an innovative step forward for clean energy and sustainability around the globe.
The microbiome had been at the forefront of a lot of research and news in the past few years. Now, a new study published in Nature Microbiology has linked specific microbiome changes with depression and quality of life. The largest of its kind to-date, the research was made possible by over 2000 participants from the Flemish Gut Flora Project and the Dutch LifeLines DEEP project. The results may lead to novel therapies for people suffering from this debilitating mental illness.
A microchip engineer might seem like an odd fit for a keynote speaker at an event focused on cell therapy, but at Science for health Peter Peumans will be presenting one of the day’s visionary talks. Peumans will draw on his experience with the tech powerhouse imec to give us an insider’s perspective on the role new chip technologies may soon take on in the cell therapy field.
In this article, V-Bio Ventures introduces one of their portfolio companies, OCTIMET. This Belgian oncology startup just added a new member to its executive team, with the appointment of Shelley Margetson as CEO. It’s exciting times for OCTIMET, who are gearing up for a series B with their sights set on potential partners in China.
Science for health is Belgium’s new research event, set to promote more collaborations in our stellar life sciences ecosystem. The September event will bring together experts from across the board; academics, industry leaders, clinicians and service providers; facilitating the formation of new research connections. The ultimate aim is not only to showcase Belgian research, but to create value for patients by encouraging new and innovative partnerships. For the inaugural 2019 edition, the focus is on the exciting field of cell therapy.
This month marked the crystal anniversary of the life sciences networking event Knowledge for Growth. The event was a huge success, with 1300+ attendees representing 600+ companies from 20+ countries around the world. The theme for this year was “Precision in Life Sciences”, with the fascinating plenary talks discussing the effect of digitalization on healthcare.
Just days before KBC Securities’ "State of the Union" announcement on how well Belgian biotech has been faring in 2019, Confo Therapeutics closed a terrific series A financing round. The company raised 30 million euros, which will be used to accelerate their drug discovery activities using their camelid-based ConfoBody™ technology.
Bioscience engineers at KU Leuven have created a record-breaking hydrogen gas panel. The panel is capable of producing 250 liters of hydrogen gas per day; enough that just 20 panels could provide a family’s electricity and heating needs for a whole European winter. The Belgian device is an innovative step forward for clean energy and sustainability around the globe.
The microbiome had been at the forefront of a lot of research and news in the past few years. Now, a new study published in Nature Microbiology has linked specific microbiome changes with depression and quality of life. The largest of its kind to-date, the research was made possible by over 2000 participants from the Flemish Gut Flora Project and the Dutch LifeLines DEEP project. The results may lead to novel therapies for people suffering from this debilitating mental illness.